Cybrexa data support its alphalex™ technology

Cybrexa Therapeutics reports preclinical data supporting the potential of its proprietary alphalex™ technology platform.

Results from multiple preclinical studies demonstrate that alphalex™ successfully enables the combination of a diverse range of structurally unique PARP inhibitors with DNA damaging chemotherapies in doses that effectively induce significant tumor cell killing, representing a new approach to target homologous recombination deficiency (HRD)-negative cancers without causing significant bone marrow toxicity. more